Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the asa study group in Taiwan

Ti Kai Lee, Kin Wei A Chan, Zei Shung Huang, Sien Kiat Ng, Ruey Tay Lin, Helen L. Po, Rey Yue Yuan, Ming Liang Lai, Tso Wen Chang, Sui Hing Yan, Jong Chyou Deng, Lu Han Liu, Kei Yee Lee, Sian King Lie, Shing Ming Sung, Han Hwa Hu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This randomized double-blind controlled study was carried out to investigate the effect of 100 mg acetylsalicylic acid (ASA) per day on the secondary prevention of ischemic stroke. Patients who suffered a first ischemic stroke from 13 participating hospitals were enrolled. They were independent or only partially dependent in activities of daily living and all had received brain CT for diagnosis. Eligible patients were randomly allocated to the 100 mg ASA or the nicametate citrate (a vasodilator) groups, and trial medications were started within three to six weeks after the onset of stroke. The primary end point was cerebral reinfarction, and intracranial hemorrhage was classified as an adverse event. Four hundred and sixty-six patients participated in this study; and 222 cases (136 males and 86 females) were allocated to the ASA group while 244 cases (150 males and 94 females) were assigned to the nicametate group. No significant difference in baseline characteristics between the two groups was observed. Cerebral reinfarction developed 6.3% (14/222) in the ASA group and 11.9% (29/244) in the nicametate group. According to the Cox's proportional hazards model, the estimated risk ratio (ASA group vs. nicametate group) was 0.538, with a 95% confidence interval of 0.284-1.019. The result was of borderline statistical significance. The risk for cerebral reinfarction was reduced by almost 50% among those who took 100 mg ASA versus those who took nicametate.

Original languageEnglish
Pages (from-to)215-224
Number of pages10
JournalThrombosis Research
Volume87
Issue number2
DOIs
Publication statusPublished - Jul 15 1997

Fingerprint

Secondary Prevention
Taiwan
Aspirin
Stroke
Intracranial Hemorrhages
Cerebral Hemorrhage
Activities of Daily Living
Vasodilator Agents
Proportional Hazards Models
Double-Blind Method
Odds Ratio
nicametate
Confidence Intervals
Brain

Keywords

  • Aspirin
  • Chinese
  • Clinical trials
  • Ischemic
  • Stroke
  • Stroke prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the asa study group in Taiwan. / Lee, Ti Kai; Chan, Kin Wei A; Huang, Zei Shung; Ng, Sien Kiat; Lin, Ruey Tay; Po, Helen L.; Yuan, Rey Yue; Lai, Ming Liang; Chang, Tso Wen; Yan, Sui Hing; Deng, Jong Chyou; Liu, Lu Han; Lee, Kei Yee; Lie, Sian King; Sung, Shing Ming; Hu, Han Hwa.

In: Thrombosis Research, Vol. 87, No. 2, 15.07.1997, p. 215-224.

Research output: Contribution to journalArticle

Lee, TK, Chan, KWA, Huang, ZS, Ng, SK, Lin, RT, Po, HL, Yuan, RY, Lai, ML, Chang, TW, Yan, SH, Deng, JC, Liu, LH, Lee, KY, Lie, SK, Sung, SM & Hu, HH 1997, 'Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the asa study group in Taiwan', Thrombosis Research, vol. 87, no. 2, pp. 215-224. https://doi.org/10.1016/S0049-3848(97)00121-7
Lee, Ti Kai ; Chan, Kin Wei A ; Huang, Zei Shung ; Ng, Sien Kiat ; Lin, Ruey Tay ; Po, Helen L. ; Yuan, Rey Yue ; Lai, Ming Liang ; Chang, Tso Wen ; Yan, Sui Hing ; Deng, Jong Chyou ; Liu, Lu Han ; Lee, Kei Yee ; Lie, Sian King ; Sung, Shing Ming ; Hu, Han Hwa. / Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the asa study group in Taiwan. In: Thrombosis Research. 1997 ; Vol. 87, No. 2. pp. 215-224.
@article{b4086a2f0f4346308396d3b077801533,
title = "Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the asa study group in Taiwan",
abstract = "This randomized double-blind controlled study was carried out to investigate the effect of 100 mg acetylsalicylic acid (ASA) per day on the secondary prevention of ischemic stroke. Patients who suffered a first ischemic stroke from 13 participating hospitals were enrolled. They were independent or only partially dependent in activities of daily living and all had received brain CT for diagnosis. Eligible patients were randomly allocated to the 100 mg ASA or the nicametate citrate (a vasodilator) groups, and trial medications were started within three to six weeks after the onset of stroke. The primary end point was cerebral reinfarction, and intracranial hemorrhage was classified as an adverse event. Four hundred and sixty-six patients participated in this study; and 222 cases (136 males and 86 females) were allocated to the ASA group while 244 cases (150 males and 94 females) were assigned to the nicametate group. No significant difference in baseline characteristics between the two groups was observed. Cerebral reinfarction developed 6.3{\%} (14/222) in the ASA group and 11.9{\%} (29/244) in the nicametate group. According to the Cox's proportional hazards model, the estimated risk ratio (ASA group vs. nicametate group) was 0.538, with a 95{\%} confidence interval of 0.284-1.019. The result was of borderline statistical significance. The risk for cerebral reinfarction was reduced by almost 50{\%} among those who took 100 mg ASA versus those who took nicametate.",
keywords = "Aspirin, Chinese, Clinical trials, Ischemic, Stroke, Stroke prevention",
author = "Lee, {Ti Kai} and Chan, {Kin Wei A} and Huang, {Zei Shung} and Ng, {Sien Kiat} and Lin, {Ruey Tay} and Po, {Helen L.} and Yuan, {Rey Yue} and Lai, {Ming Liang} and Chang, {Tso Wen} and Yan, {Sui Hing} and Deng, {Jong Chyou} and Liu, {Lu Han} and Lee, {Kei Yee} and Lie, {Sian King} and Sung, {Shing Ming} and Hu, {Han Hwa}",
year = "1997",
month = "7",
day = "15",
doi = "10.1016/S0049-3848(97)00121-7",
language = "English",
volume = "87",
pages = "215--224",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the asa study group in Taiwan

AU - Lee, Ti Kai

AU - Chan, Kin Wei A

AU - Huang, Zei Shung

AU - Ng, Sien Kiat

AU - Lin, Ruey Tay

AU - Po, Helen L.

AU - Yuan, Rey Yue

AU - Lai, Ming Liang

AU - Chang, Tso Wen

AU - Yan, Sui Hing

AU - Deng, Jong Chyou

AU - Liu, Lu Han

AU - Lee, Kei Yee

AU - Lie, Sian King

AU - Sung, Shing Ming

AU - Hu, Han Hwa

PY - 1997/7/15

Y1 - 1997/7/15

N2 - This randomized double-blind controlled study was carried out to investigate the effect of 100 mg acetylsalicylic acid (ASA) per day on the secondary prevention of ischemic stroke. Patients who suffered a first ischemic stroke from 13 participating hospitals were enrolled. They were independent or only partially dependent in activities of daily living and all had received brain CT for diagnosis. Eligible patients were randomly allocated to the 100 mg ASA or the nicametate citrate (a vasodilator) groups, and trial medications were started within three to six weeks after the onset of stroke. The primary end point was cerebral reinfarction, and intracranial hemorrhage was classified as an adverse event. Four hundred and sixty-six patients participated in this study; and 222 cases (136 males and 86 females) were allocated to the ASA group while 244 cases (150 males and 94 females) were assigned to the nicametate group. No significant difference in baseline characteristics between the two groups was observed. Cerebral reinfarction developed 6.3% (14/222) in the ASA group and 11.9% (29/244) in the nicametate group. According to the Cox's proportional hazards model, the estimated risk ratio (ASA group vs. nicametate group) was 0.538, with a 95% confidence interval of 0.284-1.019. The result was of borderline statistical significance. The risk for cerebral reinfarction was reduced by almost 50% among those who took 100 mg ASA versus those who took nicametate.

AB - This randomized double-blind controlled study was carried out to investigate the effect of 100 mg acetylsalicylic acid (ASA) per day on the secondary prevention of ischemic stroke. Patients who suffered a first ischemic stroke from 13 participating hospitals were enrolled. They were independent or only partially dependent in activities of daily living and all had received brain CT for diagnosis. Eligible patients were randomly allocated to the 100 mg ASA or the nicametate citrate (a vasodilator) groups, and trial medications were started within three to six weeks after the onset of stroke. The primary end point was cerebral reinfarction, and intracranial hemorrhage was classified as an adverse event. Four hundred and sixty-six patients participated in this study; and 222 cases (136 males and 86 females) were allocated to the ASA group while 244 cases (150 males and 94 females) were assigned to the nicametate group. No significant difference in baseline characteristics between the two groups was observed. Cerebral reinfarction developed 6.3% (14/222) in the ASA group and 11.9% (29/244) in the nicametate group. According to the Cox's proportional hazards model, the estimated risk ratio (ASA group vs. nicametate group) was 0.538, with a 95% confidence interval of 0.284-1.019. The result was of borderline statistical significance. The risk for cerebral reinfarction was reduced by almost 50% among those who took 100 mg ASA versus those who took nicametate.

KW - Aspirin

KW - Chinese

KW - Clinical trials

KW - Ischemic

KW - Stroke

KW - Stroke prevention

UR - http://www.scopus.com/inward/record.url?scp=0030740971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030740971&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(97)00121-7

DO - 10.1016/S0049-3848(97)00121-7

M3 - Article

C2 - 9259112

AN - SCOPUS:0030740971

VL - 87

SP - 215

EP - 224

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 2

ER -